BNN.XETRA BRAIN Biotech AG
- Market cap
- EUR 57.2M
- P/E
- -
- P/B
- 9.62x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is BNN.XETRA undervalued?
Graham numberThe Graham number of BRAIN Biotech AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BRAIN Biotech AG fundamental analysis
No fundamental analysis for BRAIN Biotech AG yet.
BRAIN Biotech AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. …
Full company profileBRAIN Biotech AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BRAIN Biotech AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 22.8M | 24.1M | 27.1M | 38.6M | 38.2M | 38.4M | 49.5M | 55.3M | 54.6M | 49.6M | 46.2M |
| Gross Profit | 11.4M | 12.7M | 13.4M | 21.1M | 21.2M | -1.95M | 1.43M | 3.47M | 401K | 2.01M | 10.2M |
| Operating Income | -13.8M | -9.37M | -10.0M | -5.65M | -8.87M | -6.55M | -7.53M | -6.72M | -8.85M | -8.51M | -8.80M |
| EBITDA | -12.6M | -7.55M | -5.19M | -5.71M | -2.78M | 2.01M | -1.30M | -1.98M | -4.23M | -4.17M | -3.98M |
| Net Income | -14.7M | -9.61M | -8.28M | -10.5M | -9.68M | -4.97M | -6.59M | -8.28M | -11.1M | -11.7M | -13.2M |
| EPS | -0.97 | -0.58 | -0.46 | -0.58 | -0.52 | -0.25 | -0.30 | -0.38 | -0.51 | -0.54 | -0.61 |
| Balance Sheet | |||||||||||
| Total Assets | 47.5M | 68.5M | 74.5M | 66.1M | 72.2M | 77.7M | 78.0M | 70.9M | 88.7M | 66.3M | 59.4M |
| Total Liabilities | 20.6M | 21.1M | 43.8M | 49.0M | 46.0M | 35.9M | 43.7M | 47.9M | 74.9M | 64.5M | 66.5M |
| Shareholders' Equity | 26.7M | 47.2M | 25.8M | 12.2M | 20.8M | 38.8M | 29.6M | 21.8M | 12.6M | 1.84M | -7.12M |
| Cash & Short-term Investments | 18.7M | 39.0M | 25.8M | 15.2M | 19.0M | 24.7M | 8.81M | 5.41M | 27.3M | 6.32M | 940K |
| Total Debt | 9.69M | 9.70M | 27.8M | 28.4M | 30.6M | 11.7M | 11.1M | 25.3M | 29.8M | 24.0M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.68M | -5.76M | -5.42M | -3.38M | -4.77M | -3.91M | -1.49M | -4.22M | -3.58M | -9.23M | -4.74M |
| Capital Expenditure | 1.23M | 1.08M | 1.51M | 6.64M | 2.86M | 1.26M | 6.08M | 2.64M | 1.73M | 1.53M | 2.69M |
| Free Cash Flow | -9.91M | -6.84M | -6.93M | -10.0M | -7.63M | -5.17M | -7.57M | -6.86M | -5.31M | -10.8M | -4.74M |
| Ratios | |||||||||||
| ROE | -55.1% | -20.4% | -32.1% | -85.8% | -46.6% | -12.8% | -22.2% | -38.0% | -88.2% | -637.8% | - |
| ROA | -30.9% | -14.0% | -11.1% | -15.9% | -13.4% | -6.4% | -8.4% | -11.7% | -12.5% | -17.7% | -22.3% |
| Net Profit Margin | -64.5% | -39.9% | -30.6% | -27.2% | -25.3% | -13.0% | -13.3% | -15.0% | -20.4% | -23.7% | -28.7% |
| Debt to Equity | 0.36x | 0.21x | 1.08x | 2.32x | 1.47x | 0.30x | 0.37x | 1.16x | 2.36x | 13.05x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BRAIN Biotech AG dividends
BRAIN Biotech AG has not paid dividends in the last 9 fiscal years.
Who owns BRAIN Biotech AG
- Insiders 58.40%
- Institutions 8.48%
- Public & others 33.12%
- Shares outstanding 21.8M
- Free float 9.09M
BRAIN Biotech AG company profile
- Company name
- BRAIN Biotech AG
- Ticker
- BNN.XETRA
- ISIN
- DE0005203947
- Exchange
- XETRA Stock Exchange
- Sector
- Basic Materials
- Industry
- Biotechnology
- Employees
- 280
- Fiscal year end
- September
- Address
- DarmstAedter Strasse 34-36, Zwingenberg, Germany, 64673
- Phone
- 49 62 51 9331 0
- Website
- brain-biotech.com
About BRAIN Biotech AG
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.
BRAIN Biotech AG management
9- Dr. Sven K. WeberCEO & Chairman of the Executive Board · born 1982
- Mr. Ulrich PutschCo-Founder
- Mr. Michael SchneidersCFO & Member of Management Board · born 1970
- Dr. Ute DechertVice President of Human Resources & Processes · born 1961
- Dr. Jurgen EckConsultant · born 1962
- Dr. Martin LangerMD & Executive VP · born 1965
- Dr. Alexander PelzerVP and Head of Research & Development - Zwingenberg · born 1986
- Mr. Robbert Michael HoekstraHead of Group Finance · born 1978
- Mr. Johan Jansen-StorbackaExecutive VP of BRAIN Biocatalysts enzyme products business